- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00326105
Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive Disorders (PEARL)
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo- Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) in Combination With an Antidepressant in the Treatment of Patients With Major Depressive Disorder With Inadequate Response to an Antidepressant Treatment (PEARL STUDY)
The purpose of this study is to evaluate the efficacy of quetiapine SR in combination with an antidepressant versus an antidepressant alone in patients with MDD with inadequate response to an antidepressant treatment.
PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Verwacht)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten
- Research Site
-
-
California
-
El Centro, California, Verenigde Staten
- Research Site
-
Irvine, California, Verenigde Staten
- Research Site
-
Oceanside, California, Verenigde Staten
- Research Site
-
San Diego, California, Verenigde Staten
- Research Site
-
-
Colorado
-
Pueblo, Colorado, Verenigde Staten
- Research Site
-
-
Florida
-
Coral Springs, Florida, Verenigde Staten
- Research Site
-
Deland, Florida, Verenigde Staten
- Research Site
-
Gainsville, Florida, Verenigde Staten
- Research Site
-
Hialeah, Florida, Verenigde Staten
- Research Site
-
Jacksonville, Florida, Verenigde Staten
- Research Site
-
Miami, Florida, Verenigde Staten
- Research Site
-
Orlando, Florida, Verenigde Staten
- Research Site
-
West Palm Beach, Florida, Verenigde Staten
- Research Site
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten
- Research Site
-
Roswell, Georgia, Verenigde Staten
- Research Site
-
-
Illinois
-
Hoffman Estates, Illinois, Verenigde Staten
- Research Site
-
Naperville, Illinois, Verenigde Staten
- Research Site
-
Oak Brook, Illinois, Verenigde Staten
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, Verenigde Staten
- Research Site
-
Lafayette, Indiana, Verenigde Staten
- Research Site
-
Valparaiso, Indiana, Verenigde Staten
- Research Site
-
-
Kansas
-
Prairie Village, Kansas, Verenigde Staten
- Research Site
-
Wichita, Kansas, Verenigde Staten
- Research Site
-
-
Louisiana
-
Shreveport, Louisiana, Verenigde Staten
- Research Site
-
-
Maryland
-
Glen Burnie, Maryland, Verenigde Staten
- Research Site
-
-
Massachusetts
-
Braintree, Massachusetts, Verenigde Staten
- Research Site
-
Springfield, Massachusetts, Verenigde Staten
- Research Site
-
-
Michigan
-
Clinton Township, Michigan, Verenigde Staten
- Research Site
-
Kalamazoo, Michigan, Verenigde Staten
- Research Site
-
Royal Oak, Michigan, Verenigde Staten
- Research Site
-
-
Missouri
-
St Charles, Missouri, Verenigde Staten
- Research Site
-
St. Louis, Missouri, Verenigde Staten
- Research Site
-
-
New Jersey
-
Cherry Hill, New Jersey, Verenigde Staten
- Research Site
-
Clementon, New Jersey, Verenigde Staten
- Research Site
-
-
New York
-
Cedarhurst, New York, Verenigde Staten
- Research Site
-
New York, New York, Verenigde Staten
- Research Site
-
Olean, New York, Verenigde Staten
- Research Site
-
Rochester, New York, Verenigde Staten
- Research Site
-
Staten Island, New York, Verenigde Staten
- Research Site
-
-
Ohio
-
Beechwood, Ohio, Verenigde Staten
- Research Site
-
Toledo, Ohio, Verenigde Staten
- Research Site
-
-
Oklahoma
-
Norman, Oklahoma, Verenigde Staten
- Research Site
-
Oklahoma City, Oklahoma, Verenigde Staten
- Research Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten
- Research Site
-
-
Rhode Island
-
Lincoln, Rhode Island, Verenigde Staten
- Research Site
-
-
South Carolina
-
Columbia, South Carolina, Verenigde Staten
- Research Site
-
-
Tennessee
-
Memphis, Tennessee, Verenigde Staten
- Research Site
-
-
Texas
-
Friendswood, Texas, Verenigde Staten
- Research Site
-
Houston, Texas, Verenigde Staten
- Research Site
-
San Antonio, Texas, Verenigde Staten
- Research Site
-
Wichita Falls, Texas, Verenigde Staten
- Research Site
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten
- Research Site
-
-
Virginia
-
Arlington, Virginia, Verenigde Staten
- Research Site
-
Richmond, Virginia, Verenigde Staten
- Research Site
-
-
Washington
-
Bellevue, Washington, Verenigde Staten
- Research Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Patient is able to provide written informed consent before beginning any study related procedures
- Patient has a documented clinical diagnosis of major depressive disorder
- Patient is able to understand and comply with the requirements of the study, as judged by a study investigator
Exclusion Criteria:
- Patients with a history of non-compliance as judged by the study investigator
- Patients with a known lack of response to previous treatment with quetiapine
- Patients who have participated in a clinical trial within 4 weeks of randomization
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
|---|
|
To evaluate the efficacy of quetiapine SR in combination with an antidepressant versus an antidepressant alone in MDD patients with inadequate response to an antidepressant treatment as assessed by the change from randomization to week 6 in the MADRS
|
Secundaire uitkomstmaten
Uitkomstmaat |
|---|
|
To evaluate if quetiapine SR in combination with an antidepressant improves health-related quality of life of patients with MDD, compared to an antidepressant alone
|
|
To evaluate if quetiapine SR in combination with an antidepressant reduces anxiety symptoms in patients with MDD, compared to an antidepressant alone
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Algemene publicaties
- McIntyre RS, Gorwood P, Thase ME, Liss C, Desai D, Chen J, Bauer M. Early Symptom Improvement as a Predictor of Response to Extended Release Quetiapine in Major Depressive Disorder. J Clin Psychopharmacol. 2015 Dec;35(6):706-10. doi: 10.1097/JCP.0000000000000416.
- Weisler R, Montgomery SA, Earley WR, Szamosi J, Eriksson H. Extended release quetiapine fumarate in patients with major depressive disorder: suicidality data from acute and maintenance studies. J Clin Psychiatry. 2014 May;75(5):520-7. doi: 10.4088/JCP.13m08624.
- Weisler R, McIntyre RS, Bauer M. Extended-release quetiapine fumarate in the treatment of patients with major depressive disorder: adjunct therapy. Expert Rev Neurother. 2013 Nov;13(11):1183-200. doi: 10.1586/14737175.2013.846519.
- Bauer M, Demyttenaere K, El-Khalili N, Thase ME, Papakostas GI, Szamosi J, Earley WR, Eriksson H. Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment. Int Clin Psychopharmacol. 2014 Jan;29(1):16-25. doi: 10.1097/YIC.0000000000000011.
- Clayton AH, Locklear JC, Svedsater H, McIntyre RS. Sexual functioning in patients with major depressive disorder in randomized placebo-controlled studies of extended release quetiapine fumarate. CNS Spectr. 2014 Apr;19(2):182-96. doi: 10.1017/S1092852913000631. Epub 2013 Sep 25.
- Bauer M, McIntyre RS, Szamosi J, Eriksson H. Evaluation of adjunct extended-release quetiapine fumarate on sleep disturbance and quality in patients with major depressive disorder and an inadequate response to on-going antidepressant therapy. Int J Neuropsychopharmacol. 2013 Sep;16(8):1755-65. doi: 10.1017/S146114571300031X. Epub 2013 May 14.
- Vieta E, Bauer M, Montgomery S, McIntyre RS, Szamosi J, Earley WR, Eriksson H. Pooled analysis of sustained response rates for extended release quetiapine fumarate as monotherapy or adjunct to antidepressant therapy in patients with major depressive disorder. J Affect Disord. 2013 Sep 5;150(2):639-43. doi: 10.1016/j.jad.2013.01.052. Epub 2013 Mar 14.
- El-Khalili N, Joyce M, Atkinson S, Buynak RJ, Datto C, Lindgren P, Eriksson H. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2010 Aug;13(7):917-32. doi: 10.1017/S1461145710000015. Epub 2010 Feb 23.
Studie record data
Bestudeer belangrijke data
Studie start
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- D1448C00006
- PEARL
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .